Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
agreed - today's gains should bring a lot of attention to the stock tomorrow.
the WQN security suite should prove popular with parents
the sky is the limit imho
up 4% - hope we can regain some of that early momentum
He did a fine job.
The BeesFree proprietary chemical compound is the only mixture being marketed for the bee population that combines antimicrobial agents and compounds to fight the invertebrate iridescent virus and its interaction with the Nosema fungus with other components that contrast the side effects of neonicotinoids and other nutrients and antioxidants.
HRAL up 27% today - hope the rally continues...
Impressive products
interesting video - thx
If the Prez includes algae energy in his stump speech that will be great publicity for the company
The market for mobile apps is est. at $278 billion by 2015 - the popularity of mobile applications to protect teens and children from social pressures have been on the rise in recent years. With retail sales exploding, the potential for WQN safe technology is unlimited.
agreed - we're on our way.
Yes - GlyEco has a real opportunity to corner the market on recycled glycol.
starting to move up - slowly but surely
This is an important milestone which hopefully will be followed by many more.
Wow - hope Lorenz's winning streak holds
Most polluted glycol is disposed of in our surface waters which can have a devastating impact on aquatic life. GlyEco Technology™ provides a way to reduce waste while caring for the environment.
GlyEco Announces Acquisition of Glycol Recycler Recycool
PHOENIX, AZ--(Marketwire -02/07/12)- GlyEco, Inc. (GLYE is listed on www.otcmarkets.com) (OTCQB: GLYE.OB - News) (OTC.BB: GLYE.OB - News) today announced it has signed an asset purchase agreement to acquire certain assets of Recycool, Inc. (www.recycool.net). Recycool is the dominant recycler in the Minneapolis, MN area and has been collecting and processing waste glycol -- primarily used antifreeze -- into high quality recycled antifreeze since 1995.
Recycool was founded by Marty Rosauer, Kurt Rosauer and Dennis Scott, early pioneers of the antifreeze recycling industry. Today, the company services nearly 400 customers in and around the Twin Cities metro area and will report 2011 revenues of approximately $430,000. The company's customer base is focused on vehicle dealers and repair shops, quick lube facilities, and governmental entities.
The founders and Recycool recycling team will continue to operate the Minnesota plant.
"We are very excited to have the entire Recycool group join forces with our team," stated John Lorenz, Chairman and CEO of GlyEco, Inc. "They produce high quality recycled antifreeze and have a tremendous customer service ethic. Their depth of industry experience makes the business a great asset in our growth strategy."
This purchase marks the beginning implementation of GlyEco's strategy for rapid growth through the acquisition of existing profitable recyclers. The acquired facilities will be upgraded with patent-pending GlyEco Technology™, improving production capacity, product quality and profitability. The company expects to expand its customer base and geographical reach at each location.
GlyEco Technology™ is a breakthrough green chemistry solution for recycling used glycols. This is the only process that can cleanse all five major types of waste glycols to a superior level of purity allowing our customers to utilize recycled glycols as a more sustainable resource. GlyEco Technology™ gives our customers a way to reduce waste while caring for the environment at no additional cost to them.
GlyEco CEO founded successful waste management company - you guys probably know that this guy already had a successful track record. In 1986, GlyEco CEO John D. Lorenz founded Environmental Waste of America, now known as Waste Management, currently trading at $35/share. His goal is a repeat performance for GLYE.
Kedem Sublingual Drug Delivery System Introduced at World Money Show - great exposure for the company:
PHOENIX, AZ--(Marketwire -02/07/12)- Kedem Pharmaceuticals Inc. (OTC.BB: KDMP.OB - News), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to participate February 9 -12 at the World Money Show in Orlando, Fl., Booth #609, The company CEO Dr. Hasssan Salari will be on hand to discuss with the attendees the company's progress on X-Excite, the Company's lead therapeutic drug for erectile dysfunction. The Company's second lead therapeutic drug KDM-1102, which is a new sublingual formulation of Propanolol for cardiovascular diseases. The newest drug initiated into development of Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults.
Dr. Hassan Salari, Ph.D, C.E.O. expressed, "We were pleased to Welcome the Investors at the World Money Show forum and are excited to have a platform for review by the investment community. We welcome the opportunity to inform our shareholders in more detail about our goals to commercialize our sublingual drug delivery system.
Article: One to Watch - E-Waste Systems, Inc. On a Global Scale
From Recycling Today:
http://www.ewastesystems.com/press_releases/press_release_12.14.pdf
UFFC has seen massive growth recently, including entering several franchise agreements which could potentially drive significant revenue growth. A big part of this has been the doubling of UFood Grill locations. The company recently entered a territorial franchise agreement with ASA Capital Alliance for the development of 10 UFood Grill units in British Columbia. The first unit is projected to open in Vancouver by April 2012.
34m volume smashing all records - 60X 3month ave. volume
Should be great exposure for the company
Impressive products in their generic pipeline - definitely worth a look
Agreed - hopefully the stock is turning a corner...
Alternet Systems Subsidiary Expands Portfolio of Mobile Security Services
International Mobile Security (IMS) to Distribute Proprietary Mobile Security Solutions of UK-Based Technology Firm
Press Release: Alternet Systems, Inc.
MIAMI, FL--(Marketwire -11/29/11)- Alternet Systems, Inc. (OTCQB: ALYI.PK - News) (Pinksheets: ALYI.PK - News) today announced the conclusion of an exclusive master distribution agreement between Alternet's subsidiary, International Mobile Security (IMS) and UK-based technology and systems integration company, Delma MSS, for the re-sale of Delma's mobile security solutions in the Western hemisphere.
Under this agreement IMS will be the exclusive master distributor of Delma's products and services in the Americas. Delma's technology provides mobile security solutions to global law enforcement agencies and mobile network operators, focusing on the following areas:
Asset location and recovery
Security and forensics
GSM network surveying
IMS will offer these solutions to its existing clientele and contacts within the international law enforcement community, in conjunction with its existing portfolio of proprietary mobile security services.
Delma will also offer IMS' services to its global customer base, and the two companies have already identified a series of joint research and development projects to pursue.
IMS CEO Juan Cubides explained, "The inclusion of Delma's services into our mobile security portfolio further reinforces our offering to international law enforcement agencies. It is a perfect complement to our existing technologies and sales in this vertical market segment."
"Our agreement with IMS will bring us wider geographical coverage and result in a more comprehensive solutions portfolio for our partners and customers. We are excited by the opportunities that we have already begun to explore," said Gordon McKay, CEO of Delma MMS.
No worries - up 20% for the week. Been a terrific run.
2X average volume today - a good sign esp. with more buyers than sellers.
Fresh Harvest Increases Its Distribution - in a chain of West coast stores:
NEW YORK, Nov. 7, 2011 /PRNewswire/ -- Fresh Harvest Products, Inc. (OTC QB: FRHV) announced today it has recently placed its AC LaRocco frozen pizzas in a regional retail market chain located in the state of Washington. The pizzas are currently available in 24 of the 30 stores in the chain and placement of the products are in the freezer sections. We are going to be supporting the products with in-store demonstrations and promotions, as well as using digital marketing that will be focused on the areas surrounding the locations of the stores that carry the pizzas.
About Fresh Harvest Products, Inc.
Fresh Harvest Products, Inc. is a natural and organic products company in North America. Fresh Harvest participates in several natural categories, principally frozen pizza, frozen food products and snack products, with brands including Wings of Nature™, AC LaRocco™ and TeAloe™. We sell our products through specialty and natural food distributors to stores, specialty supermarkets and retailers.
Fresh Harvest A. C. Larocco pizzas sold in Whole Foods Markets - Great potential for the company.
Alternet enters cooperative agreement with Equadorian government - In March 2011, ALYI announced a mobile wallet project for Ecuador's central bank (BCE). The project is unique in the region in that the government is participating in the regulation, but also spearheading the project. Recently ALYI's VP of sales, Mr. Jesús Luzardo said, "In Ecuador, the government is taking both the regulatory role and is actively developing the system."
First Majestic Silver - Gutierrez' most recent gig - produced $25.38 major silver 7.5m oz Ag in 2011. Now if he can do a repeat performance with SURE.
Citadel has the best pricing in the industry - merchants should go for this in a New York minute.
Agreed - IMHO Riggs is ably guiding the company step by step, and we are seeing progress not necessarily reflected in the latest 10Q. It's just a matter of time before the revenue reflects the sales and cash flow.
CERP has actually appreciated nicely after the reverse split & uplist: the stock has averaged $4.87 in 2011 compared to the equivalent of $4.00 in December of 2009. The devaluation prior to Dec. 2008 can't be blamed on the reverse split. There's every reason to expect that OriginOil will likewise see some nice appreciation.
AISystems CEO at The Air Transport IT Summit - great exposure for the company:
TORONTO, ONTARIO--(Marketwire - 06/20/11) - AISystems, Inc. (OTC.BB:ASYI - News) ("AISystems" or the "Company"), creator of jetEngine™, a revolutionary business platform software system for the airline industry, is pleased to announce that President and CEO Stephen C. Johnston has been invited to attend the SITA-hosted event The Air Transport IT Summit.
The event is being held on June 22nd and 23rd in Brussels, Belgium and is touted as "The IT Industry Event of the Year" for the airline industry. The two day conference agenda focuses on key topics of interest for airline decision makers, with leading industry speakers scheduled to present. These speakers from various airlines, airline suppliers and academia will be presenting to over 300 delegates comprised of CIO's and senior IT strategists from airlines around the world.
"I am honoured to be invited to this conference, which is SITA's main annual event" stated Stephen C. Johnston, President and Chief Executive Officer of AISystems. "All of the major airlines will be there and I have a number of key meetings lined up to discuss enrollment in our jetEngine™ BPS Beta Program."
PermaDermâ technology used on more than 150 pediatric, catastrophic burn patients. Didn't know that - sounds promising. From the website: "Regenicin, Inc. is currently working with their contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA. PermaDerm™ shows promise to save lives, reduce healthcare costs by decreasing a patient’s stay in the Critical Care Unit and reduce the need for additional surgeries..."
AVRS Updates Interference Proceedings and Notice of Allowance of Third Patent
SCOTTSDALE, AZ--(Marketwire - 05/23/11) - Advanced Voice Recognition Systems, Inc. ("AVRS") (OTC.BB:AVOI - News) is a software development company headquartered in Scottsdale, Arizona specializing in creating interface and application solutions for speech recognition technologies. Our speech recognition software and related firmware was first introduced in 1994 at an industry trade show.
Our primary assets are patents. The first U.S. Patent #5,960,447 is for a word tagging and editing system for speech recognition filed on November 13, 1995 and issued on September 28, 1999. The patent includes 42 claims covering an extremely broad base of features applicable to existing Automatic Speech Recognition (ASR) products and markets.
U.S. Patent #7,558,730 was filed on November 27, 2001 and issued on July 7, 2009. The invention discloses a system for facilitating speech recognition and transcription among users employing incompatible protocols for generating, transcribing and exchanging speech. This patent is expected to strengthen our position in voice recognition.
On March 9, 2010 the United States Patent and Trademark Office ("USPTO") declared an interference between the AVRS as Senior Party and Allvoice Developments, US LLC as Junior Party. An interference is a proceeding conducted by the USPTO in instances where two or more parties claim patent rights to the same technology. In an interference the primary purpose of the USPTO is to determine which party invented the technology first, and to award the patent to that party. The AVRS patent was filed approximately 10 months before the Allvoice Patent. On January 13, 2011, Oblon Spivak of Alexandria, Virginia, representing AVRS in the Interference proceedings, delivered oral arguments before a three judge panel of the Board of Patent Appeals and Interferences (BPAI). Oral arguments were the culmination of thousands of hours of team effort. The Company hopes to receive a timely decision.
News-Medical.net article on DARA Peripheral Neuropathy Drug
New experimental drug can help treat peripheral neuropathy in cancer patients
Published on April 11, 2011 at 5:00 AM
Although oncologists have made great strides in many aspects of cancer treatment, one area that has remained very difficult to treat is peripheral neuropathy, namely pain that can be caused by the cancer or by its treatment. In these cases patients suffer from feelings of numbness, tingling, cramping, aching or burning, even stabbing pain, often in the hands and feet. A number of widely used chemotherapeutic agents can cause peripheral neuropathy, even as they help to treat the patient's malignancy.
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Cancer doctors and palliative care specialists try many medications and remedies to relieve the painful neuropathy caused by chemotherapy, but until now there have been few treatments that specifically and effectively target neuropathic pain. DARA Biosciences of Raleigh, NC has a new drug in development, KRN5500, which looks promising for alleviating CIPN, based on early phase 2 trial results. NCI and DARA Biosciences will soon be initiating one or more joint studies of the drug in patients with CIPN.
According to Amy P. Abernethy, M.D. an oncologist who has been researching KRN5500, "One of the problems is that our usual pain medicines don't work very well for CIPN. The opioids and other medications that would be the standard therapy we would use for people who have moderate to severe cancer pain are of limited help for people with neuropathic pain, and especially chemotherapy-induced peripheral neuropathy. So what we end up doing is stacking up several different kinds of medicines that are sometimes incrementally helpful, but in aggregate generally come with many additional side effects. It's hard to guess which are going to be the most useful. Sometimes a patient's worsening CIPN is a reason for changing the chemotherapy program from the preferred treatment plan to something else."
http://www.news-medical.net/news/20110411/New-experimental-drug-can-help-treat-peripheral-neuropathy-in-cancer-patients.aspx